NUR 651 Final Study Guide Questions
With Correct Answers
Clinical |judgement |in |prescribing |includes: |correct |answers |Factoring |in |the |cost |to |the |patient |of
|the |medication |prescribed
The |route |of |excretion |of |a |volatile |drug |will |likely |be |the: |correct |answers |lungs
The |NP |chooses |to |give |cephalexin |every |8 |hours |based |on |knowledge |of |the |drugs: |correct |answers
|biological |half-life
Phenytoin |requires |that |a |trough |level |be |drawn. |Peak |and |trough |levels |are |done:
1. |When |the |drug |has |a |wide |therapeutic |range
2. |When |the |drug |will |be |administered |for |a |short |time |only
3. |When |there |is |a |high |correlation |between |the |dose |and |saturation |of |receptor |sites
4. |To |determine |if |a |drug |is |in |the |therapeutic |range |correct |answers |To |determine |if |the |drug |is |in
|the |therapeutic |range
Drugs |that |use |CYP |3A4 |isoenzymes |for |metabolism |may:
1. |Induce |the |metabolism |of |another |drug
2. |Inhibit |the |metabolism |of |another |drug
3. |Both |1 |and |2
4. |Neither |1 |nor |2 |correct |answers |Both |1 |& |2: |induce |OR |inhibit |metabolism |of |another |drug
,The |prudent |NP |would |prescribe |liquid |ibuprofen |for |a |6-year-old |because: |correct |answers |The |6-
year-old |may |not |be |able |to |swallow |pills
In |deciding |which |drug |to |prescribe |of |all |multiple |drugs |used |to |treat |a |condition, |the |NP |chooses
|drug |A |because: |correct |answers |It |will |be |taken |twice |daily |at |home
Your |patient |asks |the |difference |in |drug |effects |between |men |and |women. |What |should |the |NP
|know |about |the |differences |between |pharmacokinetics |of |men |and |women? |correct |answers
|Percentage |of |fat |differs |between |genders
Drugs |that |have |a |significant |first-pass |effect: |correct |answers |Are |rapidly |metabolized |by |the |liver
|and |may |have |little |if |any |desired |action
Azithromycin |dosing |requires |the |first |days |dosage |be |twice |those |of |the |other |4 |days |of |the
|prescription. |This |is |considered |a |loading |dose. |Loading |doses: |correct |answers |Rapidly |achieve
|drug |levels |in |the |theraputic |range
The |point |in |time |on |the |drug |concentration |curve |that |indicates |the |first |sign |of |a |therapeutic |effect
|is |the: |correct |answers |onset |of |action
Drugs |that |are |receptor |agonists |may |demonstrate |what |property? |correct |answers |Describes |the
|extent |of |effect |(response) |produced |by |a |given |drug |concentration |(dose)
Shows |the |relationship |between |the |dosage/concentration |and |the |effect |of |the |drug |concentration
Therapeutic |window |(range) |correct |answers |The |range |of |plasma |drug |concentration |with |high
|probability |of |therapeutic |response |
Provides |a |fixed |comparison |for |drug |safety
What |is |a |narrow |therapeutic |window? |correct |answers |A |drug |that |has |little |difference |between
|therapeutic |and |toxic |doses
, Treatment |goals |in |prescribing |should |be: |correct |answers |Patient |centered
storage |reservoirs: |correct |answers |Fat |and |tissue |that |the |drug |has |been |distributed |to
Passive |monitoring: |correct |answers |patient |is |educated |on |expected |outcome |and |instructed |to
|contact |provider |(expected |side |effects)
A |potentially |life-threatening |adverse |response |to |ACE |inhibitors |is |angioedema. |Which |statement
|is |true |about |this |adverse |response? |correct |answers |Swelling |of |the |tongue |and |hoarseness |are |the
|most |common |sympotms.
ACE |inhibitors |are |the |drug |of |choice |in |treating |hypertension |in |diabetic |patients |because: |correct
|answers |They |improve |insulin |sensitivity
Improve |renal |hemodynamics
Reduce |the |production |of |angiotensin |II
Ray |has |been |diagnosed |with |hypertension |and |an |ACE |inhibitor |is |determined |to |be |needed. |Prior
|to |prescribing |this |drug, |the |NP |should |assess |for:
A. |Hypokalemia
B. |Impotence
C. |Decreased |renal |function
D. |Inability |to |concentrate |correct |answers |Decreased |renal |function
Criteria |for |choosing |the |most |effective |medication: |correct |answers |Consult |nationally |recognized
|guidelines |for |disease |management
With Correct Answers
Clinical |judgement |in |prescribing |includes: |correct |answers |Factoring |in |the |cost |to |the |patient |of
|the |medication |prescribed
The |route |of |excretion |of |a |volatile |drug |will |likely |be |the: |correct |answers |lungs
The |NP |chooses |to |give |cephalexin |every |8 |hours |based |on |knowledge |of |the |drugs: |correct |answers
|biological |half-life
Phenytoin |requires |that |a |trough |level |be |drawn. |Peak |and |trough |levels |are |done:
1. |When |the |drug |has |a |wide |therapeutic |range
2. |When |the |drug |will |be |administered |for |a |short |time |only
3. |When |there |is |a |high |correlation |between |the |dose |and |saturation |of |receptor |sites
4. |To |determine |if |a |drug |is |in |the |therapeutic |range |correct |answers |To |determine |if |the |drug |is |in
|the |therapeutic |range
Drugs |that |use |CYP |3A4 |isoenzymes |for |metabolism |may:
1. |Induce |the |metabolism |of |another |drug
2. |Inhibit |the |metabolism |of |another |drug
3. |Both |1 |and |2
4. |Neither |1 |nor |2 |correct |answers |Both |1 |& |2: |induce |OR |inhibit |metabolism |of |another |drug
,The |prudent |NP |would |prescribe |liquid |ibuprofen |for |a |6-year-old |because: |correct |answers |The |6-
year-old |may |not |be |able |to |swallow |pills
In |deciding |which |drug |to |prescribe |of |all |multiple |drugs |used |to |treat |a |condition, |the |NP |chooses
|drug |A |because: |correct |answers |It |will |be |taken |twice |daily |at |home
Your |patient |asks |the |difference |in |drug |effects |between |men |and |women. |What |should |the |NP
|know |about |the |differences |between |pharmacokinetics |of |men |and |women? |correct |answers
|Percentage |of |fat |differs |between |genders
Drugs |that |have |a |significant |first-pass |effect: |correct |answers |Are |rapidly |metabolized |by |the |liver
|and |may |have |little |if |any |desired |action
Azithromycin |dosing |requires |the |first |days |dosage |be |twice |those |of |the |other |4 |days |of |the
|prescription. |This |is |considered |a |loading |dose. |Loading |doses: |correct |answers |Rapidly |achieve
|drug |levels |in |the |theraputic |range
The |point |in |time |on |the |drug |concentration |curve |that |indicates |the |first |sign |of |a |therapeutic |effect
|is |the: |correct |answers |onset |of |action
Drugs |that |are |receptor |agonists |may |demonstrate |what |property? |correct |answers |Describes |the
|extent |of |effect |(response) |produced |by |a |given |drug |concentration |(dose)
Shows |the |relationship |between |the |dosage/concentration |and |the |effect |of |the |drug |concentration
Therapeutic |window |(range) |correct |answers |The |range |of |plasma |drug |concentration |with |high
|probability |of |therapeutic |response |
Provides |a |fixed |comparison |for |drug |safety
What |is |a |narrow |therapeutic |window? |correct |answers |A |drug |that |has |little |difference |between
|therapeutic |and |toxic |doses
, Treatment |goals |in |prescribing |should |be: |correct |answers |Patient |centered
storage |reservoirs: |correct |answers |Fat |and |tissue |that |the |drug |has |been |distributed |to
Passive |monitoring: |correct |answers |patient |is |educated |on |expected |outcome |and |instructed |to
|contact |provider |(expected |side |effects)
A |potentially |life-threatening |adverse |response |to |ACE |inhibitors |is |angioedema. |Which |statement
|is |true |about |this |adverse |response? |correct |answers |Swelling |of |the |tongue |and |hoarseness |are |the
|most |common |sympotms.
ACE |inhibitors |are |the |drug |of |choice |in |treating |hypertension |in |diabetic |patients |because: |correct
|answers |They |improve |insulin |sensitivity
Improve |renal |hemodynamics
Reduce |the |production |of |angiotensin |II
Ray |has |been |diagnosed |with |hypertension |and |an |ACE |inhibitor |is |determined |to |be |needed. |Prior
|to |prescribing |this |drug, |the |NP |should |assess |for:
A. |Hypokalemia
B. |Impotence
C. |Decreased |renal |function
D. |Inability |to |concentrate |correct |answers |Decreased |renal |function
Criteria |for |choosing |the |most |effective |medication: |correct |answers |Consult |nationally |recognized
|guidelines |for |disease |management
